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Background: In England, the National Institute for Health and Care Excellence (NICE) produces guidelines for the
management of hypertension. In 2006, the NICE guidelines introduced an ethnic-age group algorithm based on the
2004 British Hypertension Society guidelines to guide antihypertensive drug prescription.
Methods: A longitudinal retrospective study with 15933 hypertensive patients aged 18 years or over and registered
with 28 general practices in Wandsworth, London in 2007 was conducted to assess variations in antihypertensive
prescribing. Logistic models were used to measure variations in the odds of being prescribed the 2006 NICE first
line recommended monotherapy among NICE patient groups over the period.
Results: From 2000 to 2007, the percentage of patients prescribed the recommended monotherapy increased
from 54.2% to 61.4% (p < 0.0001 for annual trend). Over the study period, black patients were more likely to be
prescribed the recommended monotherapy than younger non-black patients (OR 0.16, 95% CI 0.12 – 0.21) and
older non-black patients (OR 0.49, 95% CI 0.37 – 0.65). After the introduction of the NICE guidelines there was an
increase in the NICE recommended monotherapy (OR 1.44, 95% CI 1.19 – 1.75) compared with the underlying
trend. Compared to black patients, an increase in the use of recommended monotherapy was observed in younger
non-black patients (OR 1.49, 95% CI 1.17 – 1.91) but not in older non-black patients (OR 0.58, 95% CI 0.46 – 0.74).
Conclusion: The introduction of the 2006 NICE guideline had the greatest impact on prescribing for younger
non-black patients. Lower associated increases among black patients may be due to their higher levels of recommended
prescribing at baseline. The analysis suggests that guidelines did not impact equally on all patient groups.
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Antihypertensive prescribingBackground
Observational studies have consistently shown that fewer
than 40% of hypertensive patients worldwide have con-
trolled blood pressure [1]. Hypertensive patients either
without treatment or with inappropriate therapy are an
important cause of the current low rates of blood pres-
sure control [1,2]. Lack of treatment intensification or
‘clinical inertia’ has been recognized as a frequent cause
of uncontrolled blood pressure in hypertensive patients* Correspondence: l.barrera-vergara08@imperial.ac.uk
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reproduction in any medium, provided the ormanaged in primary care [3]. Clinical guidelines are pro-
duced, and frequently updated, to guide physicians on
choosing optimal antihypertensive therapy as a strategy
to reduce clinical inertia [4,5].
Physician criteria for antihypertensive prescribing may
differ from that established in clinical guidelines. Surveys
have revealed sub-optimal use of clinical guidelines by
physicians for prescribing antihypertensive drug therapy
[6-15]. This may be due to concerns among physicians that
the clinical guideline recommendations may not apply to all
hypertensive patients in primary care [12,16-19]. Variations
in hypertension treatment across primary care practices
have additionally documented the gap between guidelines
and physician antihypertensive drug preferences [20].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Excellence (NICE) is the authoritative body for the pro-
duction of clinical guidelines [4]. The NICE guidelines are
also used as reference to measure the performance of pri-
mary care services [21]. Until the last NICE hypertension
guidelines published in 2011 [4], the management of
hypertension in England primary care was based on the
recommendations established in the 2004 NICE hyper-
tension guidelines [22]. In 2006, an NICE guidance up-
date was introduced advising that those patients of
black ethnicity and those aged 55 years or over should
be treated differently to the rest of the population in
terms of the first line antihypertensive monotherapy.
Between January and April NICE extensively promoted
that guideline and it was finally adopted in June 2006.
In England increases in antihypertensive prescribing
for hypertensive patients have been documented; how-
ever the use of antihypertensive treatments established
in the guidelines has been less explored. Because the an-
tihypertensive treatment established in the 2006 updated
NICE guidelines was based on the 2004 BHS (British
Hypertension Society) guidelines and studies already
published, these recommendations may have already
been used before the introduction of that guideline. To
assess the use of the NICE hypertension guideline rec-
ommendations by general practitioners, we examined
variations in drug antihypertensive prescribing among
hypertensive patients managed in England primary care
over a 10 years follow-up period. The recommended
treatment established in the 2006 updated NICE guide-
lines was used as the reference guideline. The impact of
the introduction of this guideline on antihypertensive
prescribing was also assessed.
Methods
The data used for this study was derived from 28 general
practices located in Wandsworth, Southwest London.
We identified all patients with essential hypertension
that had a clinical record in 2007 using diagnostic READ
codes in computerized general practice records. READ
codes are the clinical classification system used in pri-
mary care in the United Kingdom (UK). For each pa-
tient, we retrospectively extracted data on annual
antihypertensive prescribing and clinical variables regis-
tered between 2000 and 2007. The study was part of a
research programme that received ethics approval from
the Wandsworth Local Research Ethics Committee.
We only included patients without missing or unknown
record of race/ethnicity and aged 18 years or over duringTable 1 First line monotherapy treatment established in the 2
NICE group Younger than 55 years
First line monotherapy treatment Angiotensin coverting enzyme inthe study period. Patients who were registered for the
first time in the respective year were counted as newly
hypertensive patients. Data on whether the patient was
prescribed the following antihypertensive drug class:
angiotensin converting enzyme inhibitors (ACEI), beta-
blockers (BB), calcium antagonist blockers (CCB), and
diuretics (DD) was extracted annually. We defined a
patient with an additional cardiovascular comorbidity
as one who had one or more of the following diseases:
diabetes mellitus, coronary heart disease, stroke, atrial
fibrillation, renal failure and heart failure. Race/ethnicity
was based on the information provided by the patient
and registered according to that defined in the 2001
UK census [23].
We used the 2006 NICE guidelines as a reference guide-
line to assess variations in antihypertensive prescribing
over the study period. The guideline was reviewed in
January 2006 and the updated version was launched in
June 2006. Because that guideline established the recom-
mendations on the first line antihypertensive monotherapy
based on a patient’s age and race/ethnicity (Table 1), we
stratified our hypertensive population such as: black for
patients of black ethnicity at all ages, younger non-black
for patients of other ethnic origin different from black
aged below 55 years and older non-black for patients of
other ethnic origin different from black aged 55 years or
over. Therefore, the older non-black and younger non-
black patient groups include those from white, South
Asian, Other Asian and other ethnic origins [24,25].
To examine variations in antihypertensive prescribing
over the study period, we measured the following annual
percentages a) the percentage of patients on antihyper-
tensive treatment as the number of patients being pre-
scribed no antihypertensive drug, one antihypertensive
drug and two or more antihypertensive drugs over the
total number of patients in each NICE patient group; b)
the percentage of patients on ACEI, BB, CCB and DD
monotherapy as number of patients prescribed each an-
tihypertensive drug class over the number of patients on
monotherapy in each NICE patient group; c) the annual
percentage of patients on the recommended monother-
apy as the number of patients prescribed the recom-
mended monotherapy over the total number of patients
on monotherapy in each NICE patient group. Because
the recommendations established in the 2006 NICE
guidelines applied to hypertensive patients aged 18 years
or over without other cardiovascular comorbidity, we
included only this hypertensive patient category to cal-
culate the last two percentages [24,25].006 NICE hypertension guidelines
55 years older or black at any age
hibitors (ACEI) Calcium channels blockers (CCB) or Diuretics (D)
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Patient characteristics are described as means and per-
centages. Unadjusted trend analysis for the percentage of
hypertensive patients being prescribed antihypertensive
treatment, the percentage of those on antihypertensive
drug class and the percentage of those on the first line
2006 NICE recommended monotherapy between 2000
and 2007 was performed using the Stata test for trend
assessment [26].
We used generalized estimating equations (GEE) with
logit function to estimate variations in the odds ratio of
being prescribed ACEI, BB, CCB and DD as monother-
apy throughout the study period. We chose GEE models
to take into account the potential correlation among the
multiple drug prescriptions received by each patient over
the study period and so obtaining more accurate estima-
tors [27,28]. Additionally, because the GEE models meas-
ure the average variation in prescribing across population
groups [27], we ran a model for each NICE patient group
in each drug antihypertensive class. For these models, we
firstly tested the annual variation in the odds ratio includ-
ing a calendar year as a continuous variable. In order to
examine the influence of the national guidelines in the
prescription of each drug class, we added the variables for
the introduction of both the 2004 BHS guidelines and the
2006 NICE guidelines. The effect of the 2006 NICE guide-
lines on each drug-related use was measured by including
a dummy variable representing the before (2000-2005
years) and after (2006-2007 years) periods of the introduc-
tion of this guideline. The assessment of the introduction
of the BHS guidelines was performed by using a dummy
variable where the before period was between 2000 and
2003 and the after period from 2004 to 2007 [27]. The
models included all hypertensive patients registered
without additional cardiovascular comorbidity. A separated
model for those newly registered was not performed due
to the small samples in some NICE patient groups. The
independence model criterion (QIC) was used to select
the best suitable correlation structure for each model
[29]. A robust estimation for the standard errors was
performed. The model was formulated as follows:
Y ¼ β  t þ βі  BHS þ β2  NICE
The β * t term was used to adjust for the baseline trend
in prescribing so that changes in prescribing associated
with the introduction of guidelines could be attributed
to this intervention. The βі * BHS term stands for the
introduction of BHS guidelines and the β2 *NICE term
stands for the introduction of NICE guidelines.
To assess the variation in the odds ratio of being pre-
scribed the 2006 NICE first line recommended monother-
apy treatment over the period, a logistic regression model
with standard errors adjusted for practice cluster [30] forall registered patients and newly registered patients were
performed respectively. For these models, the outcome
was being prescribed the first line recommended mono-
therapy as a binary variable. The time variation of the out-
come was measured by including year as continuous
variable. The effect of the introduction of the NICE and
BHS guidelines was assessed using dummy variables as
described above. To evaluate whether or not the effect
of the introduction of the NICE guidelines varied across
the NICE patient groups, we included a term for inter-
action effect. Finally the models were adjusted for sex.
The data was analysed using STATA version 11 (Stata
Corporation, College Station, TX, USA).
Results
15933 hypertensive patients with a valid ethnicity code
were selected from the registers of the participating prac-
tices in 2007. Among them, 9085 (57.0%) were white, 3926
(24.6%) were black, 1556 (9.8%) were South Asian, 594
(3.7%) were other Asian and 772 (4.8%) belonged to other
ethnic groups. 9261 (58.1%) were over 55 years, 8755
(55%) were female and 6042 (37.90%) had at least one car-
diovascular comorbidity. The most frequently associated
comorbidity was diabetes, which was present in 3419
(21.5%) of patients, followed by coronary heart disease in
1842 (11.6%), stroke in 1145 (7.2%), atrial fibrillation in 756
(4.7%), renal failure in 670 (4.2%) and heart failure in 395
(2.5%). 4078 (44.3%) of older non-black patients had at
least one cardiovascular comorbidity compared to 555
(20.2%) of younger non-black patients (Table 2).
Use of antihypertensive treatment by number of drugs
prescribed over the period
From 2000 to 2007, the percentage of patients not pre-
scribed antihypertensive drug treatment decreased in all
NICE patient groups. The percentage decreased from
43.2% to 30.2%, from 30.6% to 13.5% and from 25.2% to
8.9% in younger non-black patients, black patients and
older non-black patients respectively (p < 0.0001, for annual
trend for all). The percentage of newly registered patients
on monotherapy prescription increased from 35.2% to
45.9%, from 38.6% to 48.6% in younger non-black patients
and older non-black patients (p < 0.0001, for annual trend
for all) respectively and from 33.7% to 45.2% for black
patients (p = 0.0002) (Table 3).
Use of antihypertensive drug class in hypertensive patients
without cardiovascular comorbidity over the period
ACEI
Between 2000 and 2007, the percentage of patients on
ACEI monotherapy changed as follows: in younger non-
black patients from 26.4% to 53.7% (p < 0.0001 for annual
trend), in older non-black patients from 18.9% to 33.4%
Table 2 Characteristics of included patients, 2007
Black patients Younger non-black patients* 0lder non-black patients** Total
Number of Patients number (%) 3926 (24.6) 2746 (17.2) 9261 (58.1) 15933
Mean age years (sd) 60.4 (13.2) 44.7 (7.8) 71.1 (9.9) 63.9 (14.5)
Male no (%) 1588 (40.5) 1493 (54.3) 4096 (44.2) 7177 (45.1)
Ethnicity different from Black number (%)
White 1936 (70.5) 7149 (77.2) 9085 (75.7)
South Asian 403 (14.7) 1153 (12.5) 1566 (12.9)
Other Asian 160 (5.8) 434 (4.7) 594 (4.9)
Other origin 247 (8.9) 525 (5.7) 772 (6.4)
Presence of cadiovascular comorbidity
No 2517 (64.1) 2191 (79.8) 5183 (55.9) 9891 (62.1)
Yes*** 1409 (35.8) 555 (20.2) 4078 (44.3) 6042 (37.9)
% Indicate percentage.
sd Standard deviation.
*Indicate those of White, Asian, Other Asian origin or other ethnic origin <55 years.
**Included those of White, Asian, Other Asian origin or other ethnic origin aged 55 years and over.
***Patients with one or more than of the follow diseases: coronary heart diseases, diabetes mellitus, heart failure, atrial fibrillation stroke or renal failure.
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9.2% to 11.7% (p = 0.260 for annual trend).
The annual mean proportion of hypertensive patients
without comorbidity on ACEI monotherapy estimated
from GEE models is shown in Figure 1. The prescription
of ACEI was higher for younger non-black patients
compared to other NICE patient groups over the period.Table 3 Variation in percentages of hypertensive patients on
2000
Newly registered* All patients
Younger non black** number (%)‡
No drug therapy 132 (43.8) 653 (43.2)
One antihypertensive drug 106 (35.2) 505 (33.4)
Two or more antihypertensive drugs 63 (20.9) 353 (23.4)
Total 301 1511
Black number (%)
No drug therapy 107 (34.6) 578 (30.6)
One antihypertensive drug 104 (33.7) 590 (30.7)
Two or more antihypertensive drugs 98 (31.7) 755 (39.3)
Total 309 1923
Older non-black*** number (%)
No drug therapy 176 (28.9) 1012 (25.2)
One antihypertensive drug 235 (38.6) 1490 (37.1)
Two or more antihypertensive drugs 198 (32.5) 1519 (37.8)
Total 609 4021
Total 1219 7455
*Patients first time registered with hypertension diagnosis over the referred year.
**Included those of White, Asian, Other Asian and other ethnic origin aged <55 yea
***Included those of White, Asian, Other Asian and other ethnic origin aged >=55 y
‡Percentage = number of patients in each drug category/ Total patient-group in eaThe models also revealed that for this patient group
there was an additional increase of 23% in the odds of
being prescribed ACEI as monotherapy (OR 1.23 95%
CI 1.10 – 1.38) after the introduction of the 2006 NICE
guideline. However, a significant variation in the use of
ACEI after the introduction of the 2006 NICE guide-
lines was not observed for black patients and olderantihypertensive treatment between 2000 and 2007
2007 p value for trend
Newly registered All patients Newly registered All patients
101 (28.1) 835 (30.2) <0.0001 <0.0001
165 (45.9) 897 (32.7) <0 0001 0.4106
93 (25.9) 1014 (36.9) 0.0623 <0.0001
359 2748
41 (17.9) 531 (13.5) <0.0001 <0.0001
103 (45.2) 1115 (28.4) 0.0002 0.0877
84 (36.8) 2280 (58.1) 0.5019 <0 0001
228 3926
49 (11.9) 831 (8.9) <0.0001 <0.0001
199 (48.6) 2854 (30.8) <0.0001 <0.0001
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Figure 1 Mean annual proportion of hypertensive patients without cardiovascular comorbidity* on drug-related monotherapy by NICE
patient groups. Percentage: number of patients on monotherapy/total of patients on monotherapy in each patient group by drug classes.
Vertical line indicated the introduction year of the BHS and NICE guidelines. *Patients without one of the follow diseases coronary heart disease,
diabetes mellitus, heart failure, atrial fibrillation, stoke or renal failure.
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(OR 1.06 95% CI 0.99 – 1.12) respectively (Figure 1).
See appendix for GEE models (Additional file 1).
Beta blockers
During 2000-2007, the percentage of patients prescribed BB
monotherapy decreased from 31.3% to 12.6%, (p < 0.0001
for annual trend) in younger non-black patients; from
23.8% to 11.6% in older non-black patients, (p < 0.0001
for annual trend) and from 18.2% to 5.6%, (p < 0.0001)
for annual trend) in black patients.
From the GEE models, a reduction in the mean annual
proportion of patients prescribed BB as monotherapy
was also observed for all NICE patient groups over the
period (Figure 1). This decline accelerated after the
introduction of the 2006 NICE guidelines. Thus, the
odds of being prescribed BB for all NICE patient
groups were as follows: for black patients (OR 0.57 95%
CI 0.45 – 0.74), for younger non-black patients (OR0.57 95% CI 0.46 – 0.71) and for older non-black (OR
0.91 95% CI 0.85 – 0.98) (Figure 1). See appendix for
GEE models (Additional file 1).
Calcium channel blockers
There was an increase in the percentage of black patients
on CCB monotherapy from 48.2% in 2000 to 58.3% in
2007 (p < 0.0001 for annual trend). The percentage stayed
constant from 22.7% in 2000 and 22.4% in 2007 in youn-
ger non-black (p = 0.102 for annual trend) and increased
from 24.4% to 29.5% (p = 0.0008 for annual trend) in older
non-black patients.
From the GEE models, the highest mean annual pro-
portion of hypertensive patients on CCB monotherapy
was observed in black patients over the study period.
The proportion steeply increased after 2005 and picked
up at 2007 (Figure 1). After the introduction of the 2006
NICE guidelines, an increase of 22% in the odds of being
prescribed CCB as monotherapy was also observed in
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contrast, there was no a significant variation in the
odds of being on CCB monotherapy for younger non-
black patients and older non-black patients, (OR 1.14
95% CI 0.99 – 1.31) and (OR 1.05 95% CI 0.99 – 1.12)
respectively (Figure 1). See appendix for GEE models
(Additional file 1).Diuretics
The percentage of black patients on DD monotherapy
was 24.3% in 2000 and 24.0% in 2007 (p = 0.2046 for an-
nual trend). There were fluctuations in this prescribing
DD pattern over the period with an increase in the per-
centage in 2005. Between 2000 and 2007 the percentage
changed from 19.1% to 11.0% (p = <0.0001 for annual
trend) in younger non-black patients and from 33.1% to
25.3% (p = 0.0001 for annual trend) in older non-black
patients.
The mean annual proportion of DD therapy estimated
from GEE models started decreasing after 2005 in all
NICE patient groups (Figure 1). The introduction of 2006
NICE guidelines was associated with an additional reduc-
tion in the odds of DD monotherapy use in all NICE
patient groups such as for black patients (OR 0.77 95%
CI 0.69 – 0.86), for younger non-black patients (OR
0.71 95% CI 0.61 – 0.81) and for older non-black patients
(OR 0.77 95% CI 0.69 – 0.86) (Figure 1). See appendix for




























Figure 2 Variation in percentage of hypertensive patients* on recomm
patients on monotherapy by each NICE patients group *100. *Patients with
heart failure, atrial fibrillation, stroke or renal failure.Use of the 2006 first line NICE recommended
monotherapy over the period
All patients without cardiovascular comorbidity
Between 2000 and 2007, the percentage of patients pre-
scribed with recommended monotherapy increased from
54.2% to 61.4% (p < 0.0001 for annual trend). For black pa-
tients, there was a change from 72.5% to 82.6% (p = 0.0001
for annual trend), for younger non-black patients from
26.4% to 53.7% (p < 0.0001 for annual trend) and for older
non-black patients from 57.4% to 55.0% (p = 0.765 for
annual trend) (Figure 2). The logistic model showed
that overall black patients were significantly more likely
to be prescribed the first line recommended monotherapy
than younger non-black (OR 0.16 95% CI 0.12 – 0.21) and
older non-black patients (OR 0.49 95% CI 0.37 – 0.65)
respectively over the study period. After the introduction
of the guidelines (period 2006 – 2007), there was an in-
crease in the use of the first line NICE recommended
monotherapy (OR 1.44 95% CI 1.19 – 1.75) compared
with the period before (2000 – 2005). Compared to black
patients, younger non-black patients were more likely to
be prescribed the NICE recommended monotherapy (OR
1.49 95% CI 1.17 – 1.91) but older patients were less likely
to be prescribed the NICE recommended treatment (OR
0.58 95% CI 0.46 – 0.74) (Table 4) (Figure 2).
Newly registered patients without cardiovascular comorbidity
From 2000 to 2007, the percentage of newly registered
















ended monotherapy. Percentage: patients on monotherapy/total
out any the follow diseases coronary heart disease, diabetes mellitus,
Table 4 Variation in the odds ratio of being prescribed the first line NICE recommended monotherapy₁ among
hypertensive patients without cardiovascular comorbidity*
All hypertensive patients Newly registered hypertensive patients
Variable Odds ratio 95% CI‡ P value Odds ratio 95% CI P value
NICE2 1.44 1.19–1.75 <0.0001 1.62 1.10–2.36 0.013
References period between 2000–2005
Interaction term NICE* guidelines groups
Younger non–black patients* NICE 1.49 1.17–1.91 0.001 1.83 1.17–2.87 0,008
Older non black patients* NICE 0.58 0.46–0.74 <0.0001 0.56 0.39–0.77 0.001
Reference
Black patients* period between 2000–2005
NICE patients groups
Younger non–black patients 0.16 0.12–0.21 <0.0001 0.12 0.07–0.19 <0.0001
Older non–black patients 0.49 0.37–0.65 <0.0001 0.55 0.39–0.77 0.001
Reference non–black patients
Year 1.02 0.98–1.05 0.247 1.10 1.01–1.20 0.037
Sex 0.89 0.79–1.00 0.079 1.00 0.84–1.19 0.977
Reference female
BHS3 1.06 0.98–1.15 0.119 0.85 0.65–1.08 0.190
Reference period between 2000 and 2003
1Based on the 2006 NICE hypertension guideline update reference 24.
*Patients without one of the follow disease: coronary heart disease, diabetes mellitus, heart failure, atrial fibrillation, disease, stroke or renal failure.
‡CI confidence interval.
2NICE a variable which stands for the period after introduction of the 2006 NICE guidelines 2006–2007.
3BHS a variable which stands for the period after the introduction of the 2004 BHS guidelines 2004–2007.
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trend). For black patients, the percentage increased from
75.3% to 86.1% (p < 0.065 for annual trend), for younger
patients from 18.8% to 58.1% (p < 0.0001 for annual trend)
and for older patients from 54.3% to 63.9% (p = 0.0442
for annual trend) (Figure 2). The logistic model showed
that over the study period, younger non-black patients
and older patients non-black were less likely to have
the first line recommended monotherapy (OR 0.12 95%
CI 0.07 – 0.19) and (OR 0.55 95% CI 0.39 – 0.77) re-
spectively compared to black patients. Compared to
period between 2000 and 2005, a significant increase in
the use of the first line recommended monotherapy
was quantified in the period between 2006 and 2007,
overall (OR 1.62 95% CI 1.10 – 2.36). After the intro-
duction of the 2006 NICE guidelines, compared to
black patients, younger non-black patients were more
likely to be prescribed the first line recommended
monotherapy (OR 1.83, 95% CI 1.17 – 2.87) but older
non-black patients were less likely to be prescribed
with the first line recommended monotherapy (OR 0.56
CI 95% 0.39 – 0.77) (Table 4) (Figure 2).
Discussion
There have been major changes in antihypertensive pre-
scribing between 2000 and 2007 in this UK primary caresetting. Over this period, the main changes were an annual
decrease in the percentage of all hypertensive patients
with no antihypertensive medication. The recommended
monotherapy treatment established in the 2006 NICE
guidelines for patients of black origin started using before
the introduction of this guideline. Black patients were add-
itionally more likely to be prescribed CCB monotherapy
after the introduction of 2006 NICE guideline. ACEI was
progressively incorporated as antihypertensive monother-
apy for younger non-black patients through the study
period. The introduction of the 2006 NICE guidelines was
associated with an additional increase in the use of ACEI
monotherapy in this patient group. There was a slight
variation in the monotherapy prescribing pattern used
for older non-black patients over the study period. Our
analysis suggests that guidelines did not impact equally
on all patient groups.
On overall 61.4% of hypertensive patients were on the
2006 NICE first line monotherapy antihypertensive
treatment at the end of the study period. The use of this
recommended monotherapy seems to start before the
introduction of these guidelines particularly in those of
black origin. Evidence from clinical trials published be-
fore the introduction of these guidelines showing a dif-
ferential antihypertensive response to CCB in patients
of black origin [31] may influenced the early use of this
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younger non-black constantly increased over the period,
the introduction of the guideline clearly reinforced its pre-
scribing among general practitioners. Thus, after the im-
plementation of the guidelines younger non-black patients
experienced a nearly 50% increase in the odds of being
prescribed the recommended monotherapy compared to
black patients. Our findings on the use of antihypertensive
treatment recommended in the national guidelines look
similar to that have been reported. In 2003, Walley et al.
reported that 54% of hypertensive patients were on the
first line antihypertensive treatment established in the
former BHS hypertension guidelines [32]. More re-
cently, in a cohort of patients with stroke, Toshcke et al.
found that the use of the antihypertensive recom-
mended treatment established in the 2004 BHS guide-
lines increased from 24% to 37% between 1997 and
2006 [33]. In a cross-sectional study of 51 general prac-
tices located in Lambeth, London, Schofield et al. also
found that 44% of hypertensive patients were pre-
scribed the 2006 guidelines recommended antihyper-
tensive treatment [34]. In addition to this overall use,
our results remarked the influence of the guidelines on
the first line prescribing particularly in younger non-
black patients.
The 2006 NICE guidelines recommended that either a
CCB or DD should be used as the first line monotherapy
in older non-black patients [24], but on overall the per-
centage of older patients on either CCB or DD slightly
decrease from 57.4% to 55.0% over the study period.
Moreover, compare to black patients, the odds of being
on that recommended monotherapy treatment was sig-
nificantly lower in older non-black patients (OR 0.49 CI
95% 0.37 – 0.65) and this prescribing pattern did not
improve after the introduction of the guidelines. This
result differ from that published by NICE in 2010 where
an increase in CCB prescribing for newly hypertensive
patients aged 55 years and older was found. However,
the report did not examine differences between black
patients and those of other ethnic origin [35]. Schofield
et al. also found that among all 2006 NICE patient groups,
older non-black patients had the lowest percentage of
those being prescribed the 2006 NICE recommended
treatment [34]. Elderly hypertensive patients may be
treated differently in routine clinical settings. For these
patients the use of higher blood pressure targets and
the prescription of few antihypertensive drugs for the
treatment of hypertension have been observed in differ-
ent surveys. This is despite guideline recommendations
state that hypertension should be actively managed in
older persons [36,37]. In general practice a low use of
DD in elderly hypertensive patients has also been reported
[7]. The divergence between the guideline recommenda-
tions and the antihypertensive treatment offered to oldernon-black patients observed in our study may also be
due to the effect of other non-cardiovascular comorbidi-
ties, side effects or individual physician preferences influ-
encing choice of antihypertensive drug made by general
practitioners [7].
The highest percentage of hypertensive patients on
CCB monotherapy was in black patients. Moreover the
introduction of the 2006 NICE guidelines was associated
with an additional increase in the use of CCB for this
NICE patient group. They were also more likely to be on
the recommended monotherapy (CCB or DD) compared
to younger non-black patients and older non-black patients
over the study period. In 2005, we had already reported
this prescribing pattern in black patients [38]. Similarly,
Schofield et al. reported that nearly 90% of black patients
were prescribed the 2006 NICE recommended antihyper-
tensive treatment among hypertensive patients treated
in primary care [34]. A differential antihypertensive treat-
ment provided to black patients has also been documented
elsewhere. In a trend analysis of the National Health and
Nutrition Examination Surveys (NHANES) between 2001
and 2010, Gu et al. found that patients of black origin not
only were more likely to be prescribed CCB or DD but also
the percentage of black patients on CCB or DD therapy
increased over the period [39]. The recommendations
established in the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pres-
sure (JNC 7) may have influenced these trends. Hence,
it seems that the recommendations on antihypertensive
treatment for black patients established in national guide-
lines have been highly adopted in clinical practice.
For all NICE patient groups there has been a significant
reduction in the use of beta blockers as monotherapy anti-
hypertensive treatment. This reduction was significantly
intensified by the introduction of the NICE guidelines.
Similarly, the 2010 NICE implementation uptake report
showed a decline in the percentage of BB usage related to
all hypertensive drugs, from nearly 25% in February 2006
to 21% in October 2009. The decline was time-related to
the introduction of the 2006 NICE guidelines [35]. In
addition to guidelines, general practitioners aware of some
evidence that beta blockers may be less effective at redu-
cing blood pressure [40], as well as of their association
with new onset diabetes [41] may contribute to the con-
stant reduction in BB use over the period. However op-
posite trends in BB prescribing have also been observed.
Using NHANES data, Gu et al. found an increase in the
use BB either as monotherapy or polytherapy between
1998 and 2010 (39). Similarly, in the analysis of the pre-
scribing antihypertensive patters in Canada between
1996 and 2006, Walker et al. found an increase in the
BB monotherapy prescribing across all Canadian prov-
inces [20]. That discrepancy may be attributed to varia-
tions in the recommendations of BB use established in
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Canadian guidelines recommended the use of BB in all
hypertensive patients aged below 60 years [42,43] and
the JNV 7 established BB a second line antihypertensive
treatment for all patients [44], the 2004 and 2006 NICE
guidelines downgraded the BB as an additional therapy for
all patients [22,24]. Hence, these observations may suggest
that the local guidelines markedly influence the antihyper-
tensive prescribing patterns among general practitioners.
Strengths and limitations
The main strength of this paper is the comparison of
trends in the management of hypertension in different
ethnic groups as the study area has a diverse population
with a higher proportion of black patients than is the
case nationally [45]. Moreover, this study showed the
variation in prescribing across the different NICE patient
groups over a 10 year period. Previous studies have
examined the impact of clinical guidelines but few have
examined the impact of a race/ethnicity treatment algo-
rithm in a long follow-up period [33]. To our knowledge,
other national interventions intend to improve antihyper-
tensive prescribing were not launched at that time. The
Quality and Outcomes Framework (QOF), a national
pay for performance program, was introduced in 2004
could indirectly motivate the use of more antihyperten-
sive medications in order to improve blood pressure
control. However this financial incentive program does
not have any particular recommendations on drug ther-
apy prescription. The findings concur with variations in
antihypertensive prescribing reported in the 2010 NICE
implementation uptake report [35].
The use of GEE models offer also some advantages in
the analysis of longitudinal data. The assessment of the
interventions across groups could be more accurate
because it calculates the standard errors taking into
account the correlation present within repeated mea-
sures [27]. Ignoring that correlation could reduce the
statistical power of the study [46]. Hence GEE models
have been found more appropriate for comparing bin-
ary outcomes in longitudinal studies than the classical
analysis of variance [46]. Further, these models render
accurate estimators despite having data with small number
of clusters [27].
The use of retrospective, routine clinical data meant
that there was a lack of information about the drug
selection criteria used by general practitioners in the
study area. Then, we cannot provide reasons for the
differences between the guideline recommendations
and our reported trends. We were only able to examine
the impact of the 2006 NICE guidelines over a 18 month
period. However the impact is consistent to the prescrib-
ing trend observed in other surveys [35]. Additionally, the
study was based on hypertensive patients registered withgeneral practices in a specific area of London. Hence, our
results may not be generalizable to other populations
including black groups living in other geographical
areas however the observed trends are in line with the
current trends in antihypertensive prescribing reported
by other authors in UK primary care [34]. Additionally,
although socio-demographic characteristics could influence
antihypertensive prescribing, the UK's National Health
Service (NHS) aims to reduce differences in treatment
among general practices across the country. UK primary
care provides universal access to care to all the population.
The guidelines apply to all patients regardless of socio-
economic status or area of residency.
Conclusion
Among hypertensive patients treated in primary care in
Wandsworth, there was a constant increase in the use
of 2006 NICE recommended antihypertensive treatment
in both younger non-black patients and black patients
between 2000 and 2007. The introduction of the 2006
NICE guidelines had the greatest impact on prescribing
for younger non-black patients. Lower guideline-associated
increases in recommended prescribing among black pa-
tients may be due to higher levels of that recommended
prescribing in this patient group at baseline. The treatment
offered to older non-black patients was less influenced by
the 2006 NICE guidelines. Hence, the ethnic-age specific
NICE guidelines influence antihypertensive prescribing
but the impact of these guidelines can vary across dif-
ferent patient groups.
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